Dear Friends and Investors,

We’re excited to invite you to a private, invitation-only investor dinner featuring Intrommune, a consumer health company with a revolutionary approach to allergy prevention.

Intrommune’s patented oral mucosal immunotherapy (OMIT) platform delivers allergenic proteins via a simple, familiar routine: brushing your teeth. This daily-use toothpaste is designed to train the immune system and help prevent life-threatening food allergies—starting with peanuts and tree nuts.

This elegant solution bridges the gap between biotech and consumer health, offering a safe, effective, and scalable approach to a massive and underserved global market.

💡 The Investment Opportunity:

• Now raising $4 million
• Minimum investment: $100,000 (lower amounts may be considered at Management’s discretion)
• Early investors within 30 days receive preferential terms
• NASDAQ IPO targeted within 36 months

Why Intrommune?

Validated Science, Consumer Simplicity
In the published Phase 1 OMEGA study for peanut allergy, patients achieved 97% adherence with zero dropouts and no cases of anaphylaxis from the therapy—a rare combination of strong clinical results and unmatched user friendliness.

Enormous Market Need
Over 33 million Americans suffer from food allergies, yet treatment options remain limited. Early and consistent food exposure has been shown to decrease food allergies by over 80%. OMIT offers a daily, non-invasive food exposure toothpaste with wide appeal for parents, caregivers, and at-risk individuals.

First-Mover Advantage
No other company combines biotech-grade science with a consumer-ready delivery format—positioning Intrommune as the clear category creator in oral allergy prevention.

Experienced Leadership
CEO Michael Nelson brings decades of operational and financing experience in healthcare, and the company is advised by Dr. Sharon Chinthrajah, a nationally recognized allergy expert.

🎯 Why You Should Attend:

This is a rare opportunity to back a biotech-powered consumer product that’s validated, scalable, and de-risked—and to meet the team behind it in a private setting.

Join a select group of investors for an insider’s view into Intrommune’s next chapter and how this product could become a daily staple for millions of families.

📍 Event Details – Strictly Limited:

Location: Del Frisco’s Double Eagle Steakhouse
10250 Santa Monica Blvd., Suite 1700,
Los Angeles, CA 90067
Date: June 23, 2025
Time: 5:30pm PDT

This event is exclusively for accredited investors, family offices, and advisors.

📩 RSVP now to secure your seat and request investment materials by contacting Skylar Rallison at srallison@opus8.com

We look forward to hosting you and exploring this rare convergence of biotech innovation and consumer-scale opportunity.

Warm regards,

Tien Wong

CEO

Opus8, Inc.